Year 2024 / Volume 116 / Number 9
Letter
Ulcerative colitis induced by obinutuzumab in a patient treated for a follicular lymphoma

501-502

DOI: 10.17235/reed.2023.10009/2023

Ana López-Mourelle, Miriam Rubiera, Sara Lamas-Álvarez, Pablo Argüelles-Estrada, Ruth de Francisco, Isabel Pérez-Martínez, Andrés Castaño-García, Sabino Riestra,

Abstract
An increasing use of immunomodulatory drugs has led to a corresponding increase in treatment-related pathologies such as inflammatory bowel disease. Here, we present a case of ulcerative colitis due to Obinutuzumab, an antiCD20 monoclonal approved for the treatment of Non-Hodgkin lymphomas.
Share Button
New comment
Comments
No comments for this article
References
1. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 2017; 377(14): 1331-1344.
2. Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010; 2(1): 14-19.
3. Wang X, Zhu Y, Zhang M, Wang H, Jiang Y, Gao P. Ulcerative Colitis Is Characterized by a Decrease in Regulatory B Cells. J Crohns Colitis 2016; 10(10): 1212-23.
4. Eckmann JD, Chedid V, Quinn KP, Bonthu N, Nehra V, Raffals LE. De novo colitis associated with rituximab in 21 patients at a tertiary center. Clin Gastroenterol Hepatol 2020; 18: 252-253.
5. Carballo-Folgoso L, Celada-Sendino M, Castaño-García A, Oliva Nacarino P, Morales Del Burgo P, Pérez-Martínez I, et al. Crohn's disease induced by ocrelizumab in a patient with multiple sclerosis. Rev Esp Enferm Dig 2022; 114(12): 766-767.
Related articles

Letter

Broadening perspectives in the treatment of chronic pouchitis

DOI: 10.17235/reed.2024.10865/2024

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Citation tools
López-Mourelle A, Rubiera M, Lamas-Álvarez S, Argüelles-Estrada P, de Francisco R, Pérez-Martínez I, et all. Ulcerative colitis induced by obinutuzumab in a patient treated for a follicular lymphoma. 10009/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 635 visits.
This article has been downloaded 71 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 09/10/2023

Accepted: 11/10/2023

Online First: 26/10/2023

Published: 09/09/2024

Article Online First time: 17 days

Article editing time: 336 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology